ABSTRACT
Introduction
Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by an abnormal megacaryocyte proliferation and an elevated platelet count, in the absence of reactive thrombocytosis, other chronic myeloproliferative disorders or a myelodysplastic syndrome (1) . Thrombotic and hemorrhagic complications have been noted, and the former are a major cause of morbidity and mortality. Cytoreductive therapy is indicated for thrombosis prevention in high risk cases, and is usually obtained with hydroxyurea, interferon or anagrelide (1, 2) . Cardiovascular (CV) adverse effects of presentation, and manifested as moderate retrosternal discomfort during mild exertion, mainly in the morning, accompanied by sweating and nausea. The complaints improved after rest or sublingual nitroglycerin. He is a smoker of 20 pack-years, with no family history of cardiovascular or hematologic disease, and was diagnosed 3 years ago with ET, based on current criteria: persistent thrombocytosis (in his case, in the range of 1.200.000 to 1.800.000 platelets per microliter), exclusion of a reactive state and absence of another myeloprolipherative disorder, as demonstrated by bone marrow aspiration and absence of Philadelphia chromosome. He had no episodes of thrombosis and occasionally presented mild epistaxis. Cytoreduction was eficiently obtained with anagrelide 2 mg daily; he was previously treated with interferon which was replaced two weeks earlier because of bad tolerance and hydroxyurea which previously stopped due to gastrointestinal upset and patients concer apout its leukemogenic potential. The physical exam revealed a patient with a good general condition and a body mass index of 25.3 kg/m2. The blood pressure was 130/80 mmHg, and the heart beat was regular, with a frequency of 80/min. No cardiac murmurs, gallop or pericardial friction rub were audible. The lungs were clear and no systemic stasis was detectable. Bilateral radial and tibial pulsations were palpable.
Complete blood count was normal, except from a discrete increase in platelet count to 450.000 per microliter. Plasma biochemistry showed normal myocardial necrosis markers, glucose, renal and liver function and ions; total and LDL cholesterol were slightly elevated (220 and 132 mg/dl respectively), with normal triglycerides.
Resting electrocardiogram (ECG) disclosed sinus rhythm, normal QRS morphology and 0.5 mm ST segment depression in midprecordial leads ( Figure 1 ). Chest X-ray was unremarkable and echocardiography showed a normal sized left ventricle with good contractility, normal valves and no pericardial fluid. Stress ECG (Bruce protocol) was stopped at the second stage (7 MET) because of important ST segment elevation in precordial leads ( Figure  2 ), while the patient reported moderate chest discomfort. Giant R waves and merging of the QRS complex with the ST segment, causing a monophasic QRS-ST complex have been also noted; these changes were more obvious after the first minute of rest ( Figure 3, Figure 4 ). The pain and the major ECG findings gradually subsided in about fifteen minutes, after repeated sublingual nitroglycerine administration. No significant troponin increase was documented during the next hours, and the diagnosis of Prinzmetal angina was established. The patient stopped smoking and was started on aspirin 100 mg, atorvastatin 20 mg, verapamil up-titrated to 480 mg (at bed-time), and isosorbide mononitrate 40 mg daily. Angina appeared more rarely subsequently. Due to recent anagrelide initiation, the drug was considered to be a potentially causative agent, and it was temporary replaced by hydroxyurea.
Coronarography revealed a single coronary vessel disease, with a 60-70% diffuse stenosis of the first segment of the left anterior descending artery (LAD), involving also the bifurcations with the first diagonal and septal branches ( Figure 5 ). Intracoronary nitroglycerine injection did not improve the obstruction. Coronary artery by-pass graft surgery or angioplasty with a drug eluting stent implantation have been discussed. The patient refused any intervention, continued the medical therapy alone, and remained with one or two episodes of mild angina weekly; he appreciates his life quality as good. Anagrelide was rechallenged two months later without angina aggravation. Holter ECG showed a few episodes of ST elevation, but no malignant ventricular arrhythmia. At four years of followup, the patient is stable as concerns both angina and the haematological aspect. 
Discussions
ET is frequently asymptomatic or the patients report vasomotor symptoms like headache, lightheadedness, syncope, atypical chest pain, acral paresthesia, livedo reticularis, erythromelalgia or transient visual disturbances (8). Although ET does not significantly affect the life expectancy, both thrombotic and hemorrhagic complications have been documented; thrombotic events, more frequent arterial, are the most feared (9) . The cumulative probability of thrombosis at 15-20 years was 17-52% in large cohorts, even when the majority of the patients were treated with cytoreductive agents and aspirin (10, 11) . The cerebrovascular circulation is the most common site of arterial thrombotic disease, followed by the coronary arteries and peripheral vasculature (12) . Venous thromboembolism is also an encountered complication of ET (2) .
Cytoreductive therapy for thrombosis prevention in ET is indicated in patients with high risk features, as are: age older than 60 years, history of prior thrombosis, extreme thrombocytosis, and, probably, JAK2V617F mutation (13) . Thromboreduction is usually obtained with hydroxyurea, interferon or anagrelide (13, 14) . There is some debate about the potential leukemogenicity of hydroxyurea, but current evidence does not attribute to the drug a definite risk in this regard; actually, transformation to acute myeloid leukemia is considered part of the natural history of myeloproliferative disorders (1, 15) .
Anagrelide is an oral imidazoquinazoline derivative that interferes with megakaryocyte proliferation and maturation (16) . Toxicity of anagrelide is mainly related to the drug's anticyclic AMP phosphodiesterase activity, resulting in direct vasodilatory and inotropic effects, with consecutive headache, palpitations, tachycardia and fluid retention. This type of side effects is dose-related and diminishes after the first months of treatment (17) . Observational studies and case reports revealed also occasional serious CV adverse effects (Table I ) associated with anagrelide, like high output heart failure, acquired idiopathic cardiomyopathy, coronary spasm and acute myocardial infarction in patients without traditional coronary disease risk factors (3-7, 18,19) . In a retrospective study, almost one third of the anagrelide treated patients experienced CV adverse events, but the majority of these side effects were mild and in only 3.9% of the patients led to treatment discontinuation (3). Caution is needed when adjudicating the potential adverse effects of a drug used to treat a condition that was by itself associated with acute coronary syndromes due to coronary thrombosis and/or spasm (20) (21) (22) (23) (24) (25) (26) (27) (28) .
Anagrelide must be used with reserve in patients with known or suspected heart disease; a CV evaluation seems prudent before anagrelide initiation, although it was noted that cardiac adverse events were not related to traditional coronary risk factors and not predictable by previous instrumental evaluation (1,3). The mechanisms by which anagrelide induces coronary artery spasm and ischemia are incomplete clarified, as long as inhibition of cyclic AMP phosphodiesterase III induces mainly vasodilator and positive inotropic effects. The drug has also an antiaggregant action, but this is significant only at higher doses than those required to reduce platelet count (18) .
Prinzmetal (variant, vasospastic) angina is characterized by transient ST elevation during the acute attack, without significant troponin increase. The coronary spasm is probably caused by a blunted endothelial function that cannot balance with flow-mediated vasodilation the nonspecific vasoconstrictor stimuli such as catecholamine, serotonin, histamine, thromboxane A2 and endothelin at the vascular smooth muscle level (29) .
Coronary spasm is usually focal and tends to recur at the same location, generally at the site of an atherosclerotic lesion (29) . However, coronary spasm can be multifocal or diffuse and can affect coronary arteries that appear normal on coronary angiography (29) . In such cases intravascular ultrasound and necroscopy almost always reveal angiographically silent atherosclerosis at the site of the spasm (29) .
If the typical ECG pattern can not be spontaneously demonstrated, but suspicion persists based on the circadian variation of angina, provocation tests as hyperventilation, cold pressor test or intracoronary acetylcholine/ ergonovine can be implemented.
Exercise treadmill testing is of limited value in variant angina, but exercise-induced spasm can occur, as it was the case in our patient. Generally speaking, ST elevation is a rare finding in ECG treadmill testing, (about 3.5% of patients), and 90% of them have critical LAD lesions; in only a minority, the coronary spasm is the dominant contributor to ischemia (30) . Electrocardiographic leads with ST-segment elevation have a good prediction value for the site of hypoperfusion and the same observation was valid in our case (31) . The particular ECG aspect of giant R and monophasic QRS-ST complex may be rarely observed, except from variant angina, in acute myocardial infarction and after percutaneous transluminal coronary angioplasty (32) .
Therapeutic options for vasospastic angina. The medical treatment of Prinzmetal angina is based on calcium channel inhibitors, long acting nitrates, and possibly the newer Rho-kinase inhibitor, fasudil (33) . Beyond this, the management of the cases with associated significant atherosclerotic coronary lesion is not standardized. For critical coronary stenosis (more than 90%), there is no doubt that revascularization is mandatory, similarly with the general patients with coronary heart disease. Good clinical evolution has been described after coronary artery by-pass grafting (34) as well as after stent placement in Prinzmetal angina with significant LAD stenosis (35) . On the contrary, the role of coronary revascularization in the treatment of vasospastic angina without important coronary stenosis is limited, since coronary spasm was frequently induced at a site different from the initial stenosis, even in the absence of restenosis after coronary stent placement (36) . The only Prinzmetal angina dedicated guidelines, the Japanese ones, advise against revascularization in patients without severe coronary lesion (37) .
We judged our case according to the European Guidelines on Myocardial Revascularization, that recommend revascularization as a class I indication for prognosis reason in any proximal LAD stenosis of more than 50%; the available options are angioplasty or coronary artery bypass graft surgery (38) .
The role of anagrelide as a trigger for coronary spasm in our case is debatable. The short time elapsed between drug initiation and angina onset remains clearly a query and it has been noted that the adverse effects of anagrelide are more frequent in the first months of treatment (17) . On the other side, Prinzmetal angina appears typically in younger, smoker, male patients with no other major coronary risk factors; and spontaneous remission is a frequent outcome of variant angina (39) .
The decision to restart anagrelide in our patient was controversial, but from the haematologist point of view, there were no other better options available for thromboreduction, as long as hydroxyurea and interferon were already bad tolerated. The general opinion is that, although the reduction of side effects might occur over time, anagrelide should be discontinued in patients who experience life-threatening adverse events (4,7,13). A more permissive approach is suggested by a case report, presenting a successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy, after left ventricular function recovery (40) .
Prognostic considerations. The natural history of Prinzmetal angina with no severe coronary lesion is generally good as long as patients avoid cigarette smoking and have good compliance with calcium antagonists therapy (33) . Patients without a coronary stenosis of 70% or more, have a 94% 1-year myocardial infarctionfree survival rate (33) . Myocardial infarction is more frequent in patients with severe (more then 90%) fixed coronary stenosis. Seventy-five percent of nonfatal myocardial infarction occurs during the first three months after symptom onset or aggravation (33) . Sudden cardiac death remains an uncommon but not negligible threat for patients with Prinzmetal angina, especially for those who continue to smoke, or stop calcium channel antagonists. A study reported 2% sudden deaths during a three year follow up; the event was not correlated with fixed coronary stenosis (41) . Implantable cardioverter defibrillators were sometimes necessary in patients with vasospastic angina and severe rhythm disturbances, even after coronary revascularization and/or correct medical treatment (42, 43) .
Conclusions
We reported this case to underline that anagrelide can be associated with severe cardiovascular adverse effects, although the majority of these side effects are benign. Taken this fact into account a cardiovascular evaluation needs to be done before anagrelide initiation especially in patients with known or suspected heart disease. If the side effects are not severe, anagrelide can be continued as their reduction might occur over time; in patients who experience life-threatening adverse events anagrelide should be discontinued. Anagrelide can be successfully rechallenged, after the recovery from its side effects, especially if other therapeutic options are unavailable.
